German biotechnology company CureVac NV has said that clinical trials for its second-generation Covid-19 vaccine are expected to start within the next few months, Reuters reports.
Earlier, the company published data that showed its next-generation shot, CV2CoV, produced neutralising antibodies in monkeys that were comparable to those produced by Pfizer Inc's approved vaccine. The efficacy was also greater than the company's first-generation vaccine, it added.
